BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lou J, Zhang L, Lv S, Zhang C, Jiang S. Biomarkers for Hepatocellular Carcinoma. Biomark Cancer. 2017;9:1-9. [PMID: 28469485 DOI: 10.1177/1179299x16684640] [Cited by in Crossref: 77] [Cited by in F6Publishing: 85] [Article Influence: 12.8] [Reference Citation Analysis]
Number Citing Articles
1 Oh S, Jo S, Kim HS, Mai VH, Endaya B, Neuzil J, Jung KH, Hong SS, Kim JM, Park S. Chemical Biopsy for GNMT as Noninvasive and Tumorigenesis-Relevant Diagnosis of Liver Cancer. Anal Chem 2023;95:1184-92. [PMID: 36602057 DOI: 10.1021/acs.analchem.2c03944] [Reference Citation Analysis]
2 Abou-fade J, Reid V, Le A, Zhang J. Differential expression of key CmPn members distinguishes histological and immune subtypes of hepatic cancers. Qeios 2022. [DOI: 10.32388/ufk906] [Reference Citation Analysis]
3 Lihong Lin, Xiuxiu Zeng, Shanyan Liang, Yunzhi Wang, Xiaoyu Dai, Yuechao Sun, Zhou Wu. Construction of a co-expression network and prediction of metastasis markers in colorectal cancer patients with liver metastasis. J Gastrointest Oncol 2022;13. [PMID: 36388701 DOI: 10.21037/jgo-22-965] [Reference Citation Analysis]
4 Sonsuz A, Bakkaloglu OK. Biomarkers in Liver Disease. Biomarkers in Medicine 2022. [DOI: 10.2174/9789815040463122010020] [Reference Citation Analysis]
5 Chen P, Jiang P, Lin Q, Zeng X, Liu T, Li M, Yuan Y, Song S, Zhang J, Huang J, Ying B, Chen J. Simultaneous Homogeneous Fluorescence Detection of AFP and GPC3 in Hepatocellular Carcinoma Clinical Samples Assisted by Enzyme-Free Catalytic Hairpin Assembly. ACS Appl Mater Interfaces 2022. [PMID: 35699181 DOI: 10.1021/acsami.2c09135] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
6 Liu Y, Wang L, Liu W. Roles of circRNAs in the Tumorigenesis and Metastasis of HCC: A Mini Review. Cancer Manag Res 2022;14:1847-56. [PMID: 35668744 DOI: 10.2147/CMAR.S362594] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Gao H, Liu Y, Demichev V, Tate S, Chen C, Zhu J, Lu C, Ralser M, Guo T, Zhu Y. Optimization of Microflow LC Coupled with Scanning SWATH and Its Application in Hepatocellular Carcinoma Tissues. J Proteome Res 2022. [PMID: 35653712 DOI: 10.1021/acs.jproteome.2c00078] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Singh R, Sharma A, Saji J, Umapathi A, Kumar S, Daima HK. Smart nanomaterials for cancer diagnosis and treatment. Nano Convergence 2022;9. [DOI: 10.1186/s40580-022-00313-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
9 Ahn H, Ryu J, Lee J, Mun SJ, Hong Y, Shin Y, Chung K, Son MJ. Generation of An Induced Pluripotent Stem Cell Line from Human Liver Fibroblasts from A Patient with Combined Hepatocellular-Cholangiocarcinoma. Cell J 2022;24:133-9. [PMID: 35451583 DOI: 10.22074/cellj.2022.7765] [Reference Citation Analysis]
10 Chinenye JM, Ifeoma ME, Ifeoma BE, Obiefuna IO, Chukwudi AO, Stephen OK. Frequency of hepatitis C and D virus among chronic hepatitis B virus carriers in a Nigerian tertiary hospital. J Public Health Epidemiol 2022;14:10-15. [DOI: 10.5897/jphe2021.1367] [Reference Citation Analysis]
11 Mahalanobis S, Apoorva, Sharma N, Luthra R, Menon T, Das A. Cancer prognosis and immune system. Microbial Crosstalk with Immune System 2022. [DOI: 10.1016/b978-0-323-96128-8.00004-3] [Reference Citation Analysis]
12 Dara H, Mali M, Aher H, Patil P, Sahu B, Arya N. Point of care diagnostics for cancer: Recent trends and challenges. Nanobioanalytical Approaches to Medical Diagnostics 2022. [DOI: 10.1016/b978-0-323-85147-3.00006-2] [Reference Citation Analysis]
13 Ameri M, Salimi H, Eskandari S, Nezafat N. Identification of potential biomarkers in hepatocellular carcinoma: A network-based approach. Informatics in Medicine Unlocked 2022. [DOI: 10.1016/j.imu.2022.100864] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Feng Z, Feng Y, Wang N. Circulating Tumor Cells in the Early Detection of Human Cancers. Handbook of Cancer and Immunology 2022. [DOI: 10.1007/978-3-030-80962-1_323-1] [Reference Citation Analysis]
15 Briones-Orta MA, Delgado-Coello B, Gutiérrez-Vidal R, Sosa-Garrocho M, Macías-Silva M, Mas-Oliva J. Quantitative Expression of Key Cancer Markers in the AS-30D Hepatocarcinoma Model. Front Oncol 2021;11:670292. [PMID: 34737944 DOI: 10.3389/fonc.2021.670292] [Reference Citation Analysis]
16 Omran MM, Mosaad S, Emran TM, Eltaweel FM, Farid K. A novel model based on interleukin 6 and insulin-like growth factor II for detection of hepatocellular carcinoma associated with hepatitis C virus. J Genet Eng Biotechnol 2021;19:168. [PMID: 34714420 DOI: 10.1186/s43141-021-00262-8] [Reference Citation Analysis]
17 Cui D, Li W, Jiang D, Wu J, Xie J, Wu Y. Advances in Multi-Omics Applications in HBV-Associated Hepatocellular Carcinoma. Front Med (Lausanne) 2021;8:754709. [PMID: 34660653 DOI: 10.3389/fmed.2021.754709] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
18 Gupta R, Kleinjans J, Caiment F. Identifying novel transcript biomarkers for hepatocellular carcinoma (HCC) using RNA-Seq datasets and machine learning. BMC Cancer 2021;21:962. [PMID: 34445986 DOI: 10.1186/s12885-021-08704-9] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
19 Xu Q, Xu H, Deng R, Li N, Mu R, Qi Z, Shen Y, Wang Z, Wen J, Zhao J, Weng D, Huang W. Landscape of Prognostic m6A RNA Methylation Regulators in Hepatocellular Carcinoma to Aid Immunotherapy. Front Cell Dev Biol 2021;9:669145. [PMID: 34422799 DOI: 10.3389/fcell.2021.669145] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
20 Pomyen Y, Budhu A, Chaisaingmongkol J, Forgues M, Dang H, Ruchirawat M, Mahidol C, Wang XW; TIGER-LC Consortium. Tumor metabolism and associated serum metabolites define prognostic subtypes of Asian hepatocellular carcinoma. Sci Rep 2021;11:12097. [PMID: 34103600 DOI: 10.1038/s41598-021-91560-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Bai Y, Qi W, Liu L, Zhang J, Pang L, Gan T, Wang P, Wang C, Chen H. Identification of Seven-Gene Hypoxia Signature for Predicting Overall Survival of Hepatocellular Carcinoma. Front Genet 2021;12:637418. [PMID: 33912215 DOI: 10.3389/fgene.2021.637418] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
22 Lin D, Reddy V, Osman H, Lopez A, Koksal AR, Rhadhi SM, Dash S, Aydin Y. Additional Inhibition of Wnt/β-Catenin Signaling by Metformin in DAA Treatments as a Novel Therapeutic Strategy for HCV-Infected Patients. Cells 2021;10:790. [PMID: 33918222 DOI: 10.3390/cells10040790] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
23 Nassar ES, Elkalbashawy YA, Kamal A, Zakaria NHE. Galectin-3 is not useful for hepatocellular carcinoma surveillance in cirrhotic patients but it may be a marker of cirrhosis development. Clin Exp Hepatol 2021;7:74-8. [PMID: 34027118 DOI: 10.5114/ceh.2021.104385] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Jin X, Fu W, Li D, Wang N, Chen J, Zeng Z, Guo J, Liu H, Zhong X, Peng H, Yu X, Sun J, Zhang X, Wang X, Xu B, Lin Y, Liu J, Kutter C, Li Y. High Expression of LINC01268 is Positively Associated with Hepatocellular Carcinoma Progression via Regulating MAP3K7. Onco Targets Ther 2021;14:1753-69. [PMID: 33727826 DOI: 10.2147/OTT.S295814] [Reference Citation Analysis]
25 Ao J, Chiba T, Kanzaki H, Kanayama K, Shibata S, Kurosugi A, Iwanaga T, Kan M, Sakuma T, Qiang N, Ma Y, Kojima R, Kusakabe Y, Nakamura M, Kobayashi K, Kiyono S, Kanogawa N, Saito T, Nakagawa R, Kondo T, Ogasawara S, Suzuki E, Nakamoto S, Muroyama R, Tawada A, Kato J, Kanda T, Maruyama H, Kato N. Serum Angiopoietin 2 acts as a diagnostic and prognostic biomarker in hepatocellular carcinoma. J Cancer 2021;12:2694-701. [PMID: 33854629 DOI: 10.7150/jca.56436] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Virzì A, Gonzalez-Motos V, Tripon S, Baumert TF, Lupberger J. Profibrotic Signaling and HCC Risk during Chronic Viral Hepatitis: Biomarker Development. J Clin Med 2021;10:977. [PMID: 33801181 DOI: 10.3390/jcm10050977] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
27 Chikhaliwala P, Schlegel W, Lang H, Chandra S. Inkjet printed patterns of polyamidoamine dendrimer functionalized magnetic nanostructures for future biosensing device application. J Mater Sci 2021;56:5802-5816. [DOI: 10.1007/s10853-020-05639-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
28 Ong JR, Bamodu OA, Khang NV, Lin YK, Yeh CT, Lee WH, Cherng YG. SUMO-Activating Enzyme Subunit 1 (SAE1) Is a Promising Diagnostic Cancer Metabolism Biomarker of Hepatocellular Carcinoma. Cells 2021;10:178. [PMID: 33477333 DOI: 10.3390/cells10010178] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
29 Larsen P, Ahmed M. Common Cellular Glycans: Biosynthesis, Modifications and Functions in Cancer and Inflammation. Comprehensive Glycoscience 2021. [DOI: 10.1016/b978-0-12-819475-1.00076-6] [Reference Citation Analysis]
30 Ahn JC, Teng PC, Chen PJ, Posadas E, Tseng HR, Lu SC, Yang JD. Detection of Circulating Tumor Cells and Their Implications as a Biomarker for Diagnosis, Prognostication, and Therapeutic Monitoring in Hepatocellular Carcinoma. Hepatology 2021;73:422-36. [PMID: 32017145 DOI: 10.1002/hep.31165] [Cited by in Crossref: 94] [Cited by in F6Publishing: 92] [Article Influence: 47.0] [Reference Citation Analysis]
31 Mbamalu C, Ekejindu I, Enweani I, Kalu S, Igwe D, Akaeze G. Hepatitis B virus precore/core region mutations and genotypes among hepatitis B virus chronic carriers in South-Eastern, Nigeria. Int J Health Sci (Qassim) 2021;15:26-38. [PMID: 33708042] [Reference Citation Analysis]
32 El Aamri M, Yammouri G, Mohammadi H, Amine A, Korri-Youssoufi H. Electrochemical Biosensors for Detection of MicroRNA as a Cancer Biomarker: Pros and Cons. Biosensors (Basel) 2020;10:E186. [PMID: 33233700 DOI: 10.3390/bios10110186] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 8.3] [Reference Citation Analysis]
33 Lee NE, Kim SH, Yu DY, Woo EJ, Kim MI, Seong GS, Lee SM, Ko JH, Kim YS. Aglycosylated antibody-producing mice for aglycosylated antibody-lectin coupled immunoassay for the quantification of tumor markers (ALIQUAT). Commun Biol 2020;3:636. [PMID: 33128033 DOI: 10.1038/s42003-020-01363-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
34 Li R, Shui L, Jia J, Wu C. Construction and Validation of Novel Diagnostic and Prognostic DNA Methylation Signatures for Hepatocellular Carcinoma. Front Genet 2020;11:906. [PMID: 32922438 DOI: 10.3389/fgene.2020.00906] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
35 Gaba RC, Elkhadragy L, Boas FE, Chaki S, Chen HH, El-Kebir M, Garcia KD, Giurini EF, Guzman G, LoBianco FV, Neto MF, Newson JL, Qazi A, Regan M, Rund LA, Schwind RM, Stewart MC, Thomas FM, Whiteley HE, Wu J, Schook LB, Schachtschneider KM. Development and comprehensive characterization of porcine hepatocellular carcinoma for translational liver cancer investigation. Oncotarget 2020;11:2686-701. [PMID: 32733642 DOI: 10.18632/oncotarget.27647] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
36 Chen F, Zhong Z, Tan HY, Wang N, Feng Y. The Significance of Circulating Tumor Cells in Patients with Hepatocellular Carcinoma: Real-Time Monitoring and Moving Targets for Cancer Therapy. Cancers (Basel) 2020;12:E1734. [PMID: 32610709 DOI: 10.3390/cancers12071734] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
37 Liu Z, Zhang Z, Mei H, Mao J, Zhou X. Distribution and clinical relevance of phospholipids in hepatocellular carcinoma. Hepatol Int 2020;14:544-55. [PMID: 32504407 DOI: 10.1007/s12072-020-10056-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
38 Robinson JL, Feizi A, Uhlén M, Nielsen J. A Systematic Investigation of the Malignant Functions and Diagnostic Potential of the Cancer Secretome. Cell Rep 2019;26:2622-2635.e5. [PMID: 30840886 DOI: 10.1016/j.celrep.2019.02.025] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 12.3] [Reference Citation Analysis]
39 Zhang W, Fu T, Guo Z, Zhang Y, Zhang L, Su H, Long Y, Ji Z, Yan Y, Shao Z. Serum miR-375 Levels Are Closely Related to Disease Progression from HBV Infection to HBV-Related Hepatocellular Carcinoma. Biomed Res Int 2020;2020:5819385. [PMID: 32382558 DOI: 10.1155/2020/5819385] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
40 Afroz A, Saleem S, Sughra K, Khan SA, Zeeshan N. Identification of Candidate Biomarkers for HCV Leading to Hepatocellular Carcinoma Differential Stages From Serum Samples. CPA 2020;16:262-272. [DOI: 10.2174/1573412914666180912111038] [Reference Citation Analysis]
41 Yavuz BG, Pestana RC, Abugabal YI, Krishnan S, Chen J, Hassan MM, Wolff RA, Rashid A, Amin HM, Kaseb AO. Origin and role of hepatic myofibroblasts in hepatocellular carcinoma. Oncotarget 2020;11:1186-201. [PMID: 32284794 DOI: 10.18632/oncotarget.27532] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
42 Yavuz BG, Pestana RC, Abugabal YI, Krishnan S, Chen J, Hassan MM, Wolff RA, Rashid A, Amin HM, Kaseb AO. Origin and role of hepatic myofibroblasts in hepatocellular carcinoma. Oncotarget 2020;11:1186-201. [PMID: 32284794 DOI: 10.18632/oncotarget.27532] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
43 Bangaru S, Marrero JA, Singal AG. Screening for hepatocellular carcinoma in viral liver disease: any new biomarkers on the horizon? Clinical Dilemmas in Viral Liver Disease 2020. [DOI: 10.1002/9781119533481.ch3] [Reference Citation Analysis]
44 Barefoot ME, Varghese RS, Zhou Y, Poto CD, Ferrarini A, Ressom HW. Multi-omic Pathway and Network Analysis to Identify Biomarkers for Hepatocellular Carcinoma. Annu Int Conf IEEE Eng Med Biol Soc 2019;2019:1350-4. [PMID: 31946143 DOI: 10.1109/EMBC.2019.8856576] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
45 Liu Y, Wang S, Zhao X, Feng Y, Bormans G, Swinnen J, Oyen R, Huang G, Ni Y, Li Y. Predicting Clinical Efficacy of Vascular Disrupting Agents in Rodent Models of Primary and Secondary Liver Cancers: An Overview with Imaging-Histopathology Correlation. Diagnostics (Basel) 2020;10:E78. [PMID: 32024029 DOI: 10.3390/diagnostics10020078] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
46 Beyoğlu D, Idle JR. Metabolomic and Lipidomic Biomarkers for Premalignant Liver Disease Diagnosis and Therapy. Metabolites 2020;10:E50. [PMID: 32012846 DOI: 10.3390/metabo10020050] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 9.0] [Reference Citation Analysis]
47 Rau KM, Liu CT, Hsiao YC, Hsiao KY, Wang TM, Hung WS, Su YL, Liu WC, Wang CH, Hsu HL, Chuang PH, Cheng JC, Tseng CP. Sequential Circulating Tumor Cell Counts in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: Monitoring the Treatment Response. J Clin Med. 2020;9. [PMID: 32071283 DOI: 10.3390/jcm9010188] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
48 Kaur H, Dhall A, Kumar R, Raghava GPS. Identification of Platform-Independent Diagnostic Biomarker Panel for Hepatocellular Carcinoma Using Large-Scale Transcriptomics Data. Front Genet 2019;10:1306. [PMID: 31998366 DOI: 10.3389/fgene.2019.01306] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
49 Allen R, Li D. Hepatocellular Carcinoma. Oncology in the Precision Medicine Era 2020. [DOI: 10.1007/978-3-030-31471-2_16] [Reference Citation Analysis]
50 Dadfar SMM, Sekula-Neuner S, Trouillet V, Liu HY, Kumar R, Powell AK, Hirtz M. Evaluation of click chemistry microarrays for immunosensing of alpha-fetoprotein (AFP). Beilstein J Nanotechnol 2019;10:2505-15. [PMID: 31921529 DOI: 10.3762/bjnano.10.241] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
51 Devcic Z, Elboraey M, Vidal L, Mody K, Harnois D, Patel T, Toskich BB. Individualized Ablation of Hepatocellular Carcinoma: Tailored Approaches across the Phenotype Spectrum. Semin Intervent Radiol 2019;36:287-97. [PMID: 31680719 DOI: 10.1055/s-0039-1698755] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
52 Cao W, Sharma M, Imam R, Yu J. Study on Diagnostic Values of Astrocyte Elevated Gene 1 (AEG-1) and Glypican 3 (GPC-3) in Hepatocellular Carcinoma. Am J Clin Pathol 2019;152:647-55. [PMID: 31305883 DOI: 10.1093/ajcp/aqz086] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
53 Kaur H, Bhalla S, Raghava GPS. Classification of early and late stage liver hepatocellular carcinoma patients from their genomics and epigenomics profiles. PLoS One 2019;14:e0221476. [PMID: 31490960 DOI: 10.1371/journal.pone.0221476] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 6.3] [Reference Citation Analysis]
54 Kaur H, Dhall A, Kumar R, Raghava GPS. Identification of Platform-Independent Diagnostic Biomarker Panel for Hepatocellular Carcinoma using Large-scale Transcriptomics Data.. [DOI: 10.1101/758250] [Reference Citation Analysis]
55 Neureiter D, Stintzing S, Kiesslich T, Ocker M. Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets. World J Gastroenterol 2019; 25(25): 3136-3150 [PMID: 31333307 DOI: 10.3748/wjg.v25.i25.3136] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 42] [Article Influence: 9.3] [Reference Citation Analysis]
56 Balaceanu LA. Biomarkers vs imaging in the early detection of hepatocellular carcinoma and prognosis. World J Clin Cases 2019; 7(12): 1367-1382 [PMID: 31363465 DOI: 10.12998/wjcc.v7.i12.1367] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
57 Madduru D, Ijaq J, Dhar S, Sarkar S, Poondla N, Das PS, Vasquez S, Suravajhala P. Systems Challenges of Hepatic Carcinomas: A Review. J Clin Exp Hepatol 2019;9:233-44. [PMID: 31024206 DOI: 10.1016/j.jceh.2018.05.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
58 Zou W, Cui J, Ren Z, Leng Y. NRAGE is a potential diagnostic biomarker of hepatocellular carcinoma. Medicine (Baltimore) 2018;97:e13411. [PMID: 30508943 DOI: 10.1097/MD.0000000000013411] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
59 Hayes CN, Zhang P, Zhang Y, Chayama K. Molecular Mechanisms of Hepatocarcinogenesis Following Sustained Virological Response in Patients with Chronic Hepatitis C Virus Infection. Viruses. 2018;10. [PMID: 30274202 DOI: 10.3390/v10100531] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
60 Ocker M. Biomarkers for hepatocellular carcinoma: What’s new on the horizon? World J Gastroenterol 2018; 24(35): 3974-3979 [PMID: 30254402 DOI: 10.3748/wjg.v24.i35.3974] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 32] [Article Influence: 5.6] [Reference Citation Analysis]
61 Lubecka K, Flower K, Beetch M, Qiu J, Kurzava L, Buvala H, Ruhayel A, Gawrieh S, Liangpunsakul S, Gonzalez T, McCabe G, Chalasani N, Flanagan JM, Stefanska B. Loci-specific differences in blood DNA methylation in HBV-negative populations at risk for hepatocellular carcinoma development. Epigenetics 2018;13:605-26. [PMID: 29927686 DOI: 10.1080/15592294.2018.1481706] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
62 Chen H, Zhang Y, Li S, Li N, Chen Y, Zhang B, Qu C, Ding H, Huang J, Dai M. Direct comparison of five serum biomarkers in early diagnosis of hepatocellular carcinoma. Cancer Manag Res 2018;10:1947-58. [PMID: 30022853 DOI: 10.2147/CMAR.S167036] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 5.8] [Reference Citation Analysis]
63 Caviglia GP, Ribaldone DG, Abate ML, Ciancio A, Pellicano R, Smedile A, Saracco GM. Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis. Scand J Gastroenterol 2018;53:734-40. [PMID: 29667463 DOI: 10.1080/00365521.2018.1459824] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
64 Zhu Y, Zhu J, Lu C, Sun P, Xie W, Zhang Q, Yue L, Zhu T, Ruan G, Aebersold R, Huang S, Guo T. Identification of protein abundance changes in biopsy-level hepatocellular carcinoma tissues using PCT-SWATH.. [DOI: 10.1101/300673] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
65 Kaur H, Bhalla S, Raghava G. Classification of early and late stage Liver Hepatocellular Carcinoma patients from their genomics and epigenomics profiles.. [DOI: 10.1101/292854] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
66 Ye F, Jia D, Lu M, Levine H, Deem MW. Modularity of the metabolic gene network as a prognostic biomarker for hepatocellular carcinoma. Oncotarget 2018;9:15015-26. [PMID: 29599922 DOI: 10.18632/oncotarget.24551] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
67 Xiao H, Zhou B, Jiang N, Cai Y, Liu X, Shi Z, Li M, Du C. The potential value of CDV3 in the prognosis evaluation in Hepatocellular carcinoma. Genes Dis 2018;5:167-71. [PMID: 30258946 DOI: 10.1016/j.gendis.2018.01.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
68 Cruz-Ramón V, Chinchilla-López P, Ramírez-Pérez O, Qi X, Méndez-Sánchez N. The Changing Face of the Diagnosis of Chronic and Malignant Liver Diseases: Potential New Biomarkers. Ann Hepatol 2018;17:14-7. [PMID: 29311406 DOI: 10.5604/01.3001.0010.7531] [Reference Citation Analysis]
69 Ye F, Jia D, Lu M, Levine H, Deem MW. Modularity of the metabolic gene network as a prognostic biomarker for hepatocellular carcinoma.. [DOI: 10.1101/224998] [Reference Citation Analysis]
70 Naryzhny S, Zgoda V, Kopylov A, Petrenko E, Kleist O, Archakov А. Variety and Dynamics of Proteoforms in the Human Proteome: Aspects of Markers for Hepatocellular Carcinoma. Proteomes 2017;5:E33. [PMID: 29168748 DOI: 10.3390/proteomes5040033] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]